Categories: News

Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

Vapotherm is scheduled to present at 9:00 am Eastern Time. The presentation will be accessible via a live webcast at https://wsw.com/webcast/blair58/vapo/1946490.

A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

About Vapotherm

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Website Information

Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.

Contacts

Investor Relations Contacts:
Mark Klausner or Mike Vallie, Westwicke, an ICR Company, ir@vtherm.com, +1 (603) 658-0011

Staff

Recent Posts

PMI Foods Donates 5,000 Pounds of Prime Ribs to City of Refuge to Help Victims of Human Trafficking

SALT LAKE CITY, July 15, 2024 /PRNewswire/ -- Parker Migliorini International (PMI Foods) just announced a…

27 mins ago

PausePoint Helps Employees and Professionals Prioritize Mental Health

PausePoint, a new mindfulness and wellbeing app designed to help professionals reclaim time, launches officially.…

27 mins ago

CareMagnus Bridges the Gaps in Multi-Channel Care

CareMagnus enhances the multi-channel and person-centred care continuum with its intelligent care management cloud platform.…

27 mins ago

Pharmaceutical Quality Management Systems Market to Be Worth $4.59 Billion by 2031 – Exclusive Report by Meticulous Research®

REDDING, Calif., July 15, 2024 /PRNewswire/ -- According to a new market research report titled, 'Pharmaceutical…

28 mins ago

Electrosurgical Devices Market to Reach USD 10.4 Billion by 2034, Fueled by Advanced Technology Ensuring Precision and Safety | Transparency Market Research

The rise in minimally invasive surgeries is a key driver for the global electrosurgical devices market…

28 mins ago